Oral Peptide Drugs Approved by FDA | ||||||
Name | Active Ingredient | Dosage Form/Administration Route | Classification | Indication | Approved Date | Company |
LINZESS | Linaclotide | Capsule/Oral | Guanylate cyclase-C agonists | Irritable Bowel Syndrome with Constipation (IBS-C); Chronic idiopathic constipation (CIC) | Aug. 20, 2012 | Allergan |
TRULANCE | Plecanatide | Tablet/Oral | Guanylate cyclase-C agonists | Chronic idiopathic constipation (CIC) | Jan. 19, 2017 | Snlix |
RYBELSUS | Semaglutide | Tablet/Oral | GLP1 Receptor Agonist | Type 2 diabetes | Sep. 20, 2019 | Novo Nordisk |
Oral Peptide Drugs in Clinical Stage | |||
Technology | Drug | Clinical Stage | Company |
Eligen | Insulin | Phase I | Emisphere Technologies (USA) |
Mycapssa | Octreotide | Phase III | Chiasma (USA) |
Peptelligence | Leuprorelin | Phase II | Enteris BioPharma (USA) |
Eligen | GLP-1 | Phase II | The University Hospital of Basel (Switzerland) |
Peptelligence | Parathyroid Hormone | Phase II | Entera Bio Ltd (Israel) |
Eligen | Salmon calcitonin | Phase III | Nordic Bioscience (Denmark) / Novartis (Switzerland) |
POD | Insulin | Phase II | Oramed (Israel) |
Oshadi Icp | Insulin | Phase I | Oshadi Drug Administration (Israel) |
Peptelligence | Salmon calcitonin | Phase II | Tarsa Therapeutics (USA) |